Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

President's cancer panel focuses on environmental chemicals

An expert panel that advises the president on cancer said Thursday that Americans are facing 'grievous harm' from chemicals in the air, food and water that have largely gone unregulated and ignored. The President's Cancer Panel called for a new national strategy that focuses on such threats in the environment and workplaces.

7 May 2010

Inflammation enzyme regulates production of brown fat tissue

Love handles, muffin tops and stomach tires - white fat tissue forms the typical curves in the notorious problem areas to store energy. Exactly the opposite happens in brown fat tissue: Instead of being stored, energy gets transformed into heat. To the dismay of many people, adults have only small amounts of this energy burner. By contrast, babies and animals in hibernation have lots of it in their bodies where it serves for heat regulation.

7 May 2010

Creator of California Tay-Sachs Disease Prevention Program among the honorees

A mere 40 years ago, parents didn't know they were carriers of the Tay-Sachs disease until after they'd given birth to a child with this fatal genetic disorder.

7 May 2010

Progestins increase chances of cancer metastasizing: Study

After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

NHLBI grants MU $8.47 million for research on cardiovascular diseases

One of the largest medical research grants ever awarded to the University of Missouri was announced today by MU scientists and administrators. The National Institutes of Health grant will help answer important questions about such prevalent health problems as high blood pressure, diabetes and stroke. The conditions are closely associated with cardiovascular disease, which is the leading cause of death in Missouri and the nation.

7 May 2010

FDA approves new oral contraceptive Natazia

The U.S. Food and Drug Administration today approved Natazia, a combination hormonal tablet for use as an oral contraceptive.

7 May 2010

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.

6 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

Whole grain barley products with low glycemic response provide favourable metabolic benefits

Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.

6 May 2010

ViaCyte granted three new U.S. patents

ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents.

6 May 2010

Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

Cancer researchers at Princess Margaret Hospital have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

Research reveals role of ovarian hormone progesterone in alteration of breast stem cells

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Pre-treatment quality-of-life scores predict malignancy in patients with pancreatic disease

Quality-of-life measures used routinely to assess treatment outcomes for patients with pancreatic disease may be used to predict both malignancy and survival for those patients, according to a study by Henry Ford Hospital.

5 May 2010

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

5 May 2010

Akela Pharma, PharmaForm file second bi-weekly Default Status Report under NP 12-203

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, are providing their second bi-weekly Default Status Report under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

5 May 2010

Australian researchers show positive effect of growth hormone on athletic performance

Australian researchers have published the results of a study, for the first time showing a positive effect of growth hormone on athletic performance.

5 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Hormone News and Research

Further Reading

President's cancer panel focuses on environmental chemicals

Inflammation enzyme regulates production of brown fat tissue

Creator of California Tay-Sachs Disease Prevention Program among the honorees

Progestins increase chances of cancer metastasizing: Study

Natazia tablets receive FDA approval for prevention of pregnancy

NHLBI grants MU $8.47 million for research on cardiovascular diseases

FDA approves new oral contraceptive Natazia

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Whole grain barley products with low glycemic response provide favourable metabolic benefits

ViaCyte granted three new U.S. patents

Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

Research reveals role of ovarian hormone progesterone in alteration of breast stem cells

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

FDA approves Provenge for treating men with advanced prostate cancer

Pre-treatment quality-of-life scores predict malignancy in patients with pancreatic disease

Diets rich in whole grain reduce risk of obesity and other diseases related to metabolic syndrome

Akela Pharma, PharmaForm file second bi-weekly Default Status Report under NP 12-203

Australian researchers show positive effect of growth hormone on athletic performance

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News